For the Inventor, By the Inventor

Enter assignee name

Bagsvaerd, Denmark

Novo Nordisk A/s

USPTO Granted Patents = 1,778

CIPO Patents = 51

EPO Patents = 506

Trademarks = 151

Forward Citations = 45,398

Loading Chart...

Loading Chart...

1,831 inventors (with patents filed for the assignee):

Jesper F Lau (89 out of 98 patents)

Peter Madsen (74 out of 79 patents)

Per Sauerberg (70 out of 99 patents)

4. Knud Erik Andersen (61 out of 73 patents)

5. Henrik Sune Andersen (45 out of 63 patents)

6. Rolf Hohlweg (45 out of 55 patents)

7. Lone Jeppesen (43 out of 60 patents)

8. Henrik Bengtsson (40 out of 42 patents)

9. Uffe Bang Olsen (40 out of 43 patents)

10. Preben H Olesen (40 out of 56 patents)

11. Tine Krogh Jo Slashedrgensen (36 out of 39 patents)

12. Thomas Kruse (34 out of 35 patents)

13. Patrick William Garibay (34 out of 36 patents)

14. Allan Svendsen (33 out of 207 patents)

15. Christian Peter Enggaard (33 out of 34 patents)

Core Competencies:

Drug Delivery Systems

Injection Devices

GLP-1 Agonists

Insulin Formulations

Antibodies

Medical Device Actuation

Sensor Systems

Diabetes Treatment

Dose Limiting Mechanisms

Piston Rod Mechanisms

Amylin Receptor Agonists

Wireless Communication in Devices

1,778 patents: Sort by Forward Citations

1. 12514822 - Oral dosing of GLP-1 compounds (2026-01-06),

2. 12485229 - Reusable torsion spring driven injection device (2025-12-02),

3. 12478741 - Drug delivery system with multipolar magnet and sensor system (2025-11-25),

4. 12433999 - Injection device incorporating a needle shield remover (2025-10-07),

5. 12427264 - Drug delivery device with plunger rod having nonuniform stopper interface (2025-09-30),

6. D1092723 - Injection device (2025-09-09),

7. 12404500 - Homing endonuclease variants (2025-09-02),

8. 12404325 - Anti IL-6 domain antibodies with fatty acid substituents (2025-09-02),

9. 12396953 - Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (2025-08-26),

10. 12390600 - Drug delivery device for delivering a predefined fixed dose (2025-08-19),

11. 12364663 - Method and equipment for fractionation of granules for use in pharmaceutical compositions (2025-07-22),

12. 12343383 - High concentration insulin formulation (2025-07-01),

13. 12337157 - Injection device for delivering a liquid drug and a method of assembly (2025-06-24),

14. 12337156 - Piston rod drive mechanism (2025-06-24),

15. 12295988 - Semaglutide in medical therapy (2025-05-13),

Novo Nordisk is a global healthcare company founded in Denmark in 1923. It specializes in the development, production, and distribution of pharmaceutical products and services. Novo Nordisk's main focus is on diabetes care, but it also offers treatments for rare bleeding disorders, growth hormone deficiencies, and obesity. With a strong commitment to scientific innovation and corporate sustainability, Novo Nordisk strives to improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

1,778 Patents

#1 in Bagsvaerd

#1 in Denmark

#556 in the World

Bagsvaerd, Denmark

Novo Nordisk A/s

Forward Citations = 45,398

1,831 inventors:

Jesper F Lau (89 out of 98 patents)

Peter Madsen (74 out of 79 patents)

Per Sauerberg (70 out of 99 patents)

4. Knud Erik Andersen (61 out of 73 patents)

5. Henrik Sune Andersen (45 out of 63 patents)

Please report any incorrect information to support@idiyas.com

Loading…